 Amylyx Pharmaceuticals Inc NASDAQ: AMLX shares are trading higher by 37.67 at 13.45 after the company announced the FDA extended the review timeline of the New Drug Application for AMX0035. Amylyx says the FDA extended the PDUFA date to allow more time to review additional analyses of data from. 